Policy Differences Among European Nations Affect Biosimilar Uptake
January 5th 2018
By Kelly Davio
ArticleWhile the European experience with biosimilars is one of significant uptake of biosimilars, individual European nations have had distinctly different levels of uptake. These differences are largely due to local variation in pricing and reimbursement, education levels, population characteristics, and stakeholder incentives.